Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 1.00 |
| ▸ | ABL1 | P00519 | 13/20 | 1.00 |
| ▸ | BCR | P11274 | 9/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 8/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 4/20 | 0.80 |
| ▸ | KDR | P35968 | 1/20 | 0.75 |
| ▸ | ABL2 | P42684 | 1/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.74 |
| ▸ | PRKCG | P05129 | 1/20 | 0.74 |
| ▸ | PRKCB | P05771 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | PRKCH | P24723 | 1/20 | 0.74 |
| ▸ | PRKCI | P41743 | 1/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.74 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782 | 1.00 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| Methane SCHEMBL5972158 | 0.99 | PDGFRA (0.98) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL2004455 | 0.95 | PDGFRA (0.91) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL3055349 | 0.94 | PDGFRA (0.89) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL9820 | 0.93 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL13498211 | 0.92 | PDGFRA (0.88) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL30197820 | 0.92 | PDGFRA (0.85) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL9677 | 0.92 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL11927842 | 0.92 | ABL1 (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL11932096 | 0.92 | PDGFRA (0.86) | PDGFRAABL1BCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626239-B1 | EZH2 INHIBITOR COMBINED WITH BTK INHIBITOR FOR TREATING TUMOR | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2024-07-03 | — | — | EP | claimed |
| CN-110240629-B | Protein degradation targeting BCR-ABL compound and antitumor application thereof | 上海科技大学 | 2023-10-03 | — | — | CN | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | claimed |
| US-12569442-B2 | Process for producing a pharmaceutical formulation comprising active substance, polymer and surfactant | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | disclosed |
| CN-119798229-A | Preparation method of imatinib dimer | 中国食品药品检定研究院 | 2025-04-11 | — | — | CN | disclosed |
| US-12226527-B2 | Gel formulations for local drug release | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-02-18 | — | — | US | disclosed |
| US-12214218-B2 | Perfusion modulated tumor dose sculpting with single dose radiotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3626239-B1 | EZH2 INHIBITOR COMBINED WITH BTK INHIBITOR FOR TREATING TUMOR | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-114656451-A | Benzamide derivative, preparation method and application | 海南医学院 | 2022-06-24 | — | — | CN | disclosed |
| EP-4003508-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | Memorial Sloan Kettering Cancer Center (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114377137-A | Combination of LSD1 inhibitors for the treatment of hematologic malignancies | 奥莱松基因组股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-109937041-B | Application of EZH2 inhibitor and BTK inhibitor in preparation of medicine for treating tumors | 江苏恒瑞医药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-109462980-B | Combination of LSD1 inhibitors for the treatment of hematologic malignancies | 奥莱松基因组股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569442-B2 | Process for producing a pharmaceutical formulation comprising active substance, polymer and surfactant | ACMSD, EXOSC10, RPS27 | PDGFRA 947/4885ABL1 3203/4885BCR 4052/4885 |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | PDGFRA 4526/4885ABL1 4810/4885BCR 4828/4885 |
| US-12214218-B2 | Perfusion modulated tumor dose sculpting with single dose radiotherapy | TP53, CTPS1, TSG101 | PDGFRA 317/4885ABL1 3654/4885BCR 4698/4885 |
| US-12226527-B2 | Gel formulations for local drug release | TREH, GALE, SLC2A8 | PDGFRA 4526/4885ABL1 4810/4885BCR 4828/4885 |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | TP53, CTPS1, TSG101 | PDGFRA 317/4885ABL1 3654/4885BCR 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.